News | Artificial Intelligence | December 10, 2018

Bay Labs Collaborating With Edwards Lifesciences on AI for Heart Disease Detection

Bay Labs’ EchoMD measurement and interpretation software for echocardiography will be integrated with Edwards’ CardioCare quality care navigation platform

Bay Labs Collaborating With Edwards Lifesciences on AI for Heart Disease Detection

December 10, 2018 – Medical artificial intelligence (AI) company Bay Labs announced a collaboration with Edwards Lifesciences focused on improving the detection of heart disease. The partnership involves multiple initiatives, including the development of new AI-powered algorithms in Bay Labs’ EchoMD measurement and interpretation software suite, the integration of EchoMD algorithms into Edwards Lifesciences’ CardioCare quality care navigation platform, and support for ongoing clinical studies at leading institutions.

Multiple EchoMD algorithms have been integrated into the CardioCare platform for investigational use to retrospectively analyze echocardiograms. The companies believe that incorporating these and future algorithms into clinical practice could help drive quality improvement and potentially increase accurate heart disease detection.

The CardioCare program combines clinical consulting expertise with a cloud-based platform to facilitate the identification, referral and care pathway management of patients with structural heart disease. CardioCare can help hospitals improve quality by reducing variability in echocardiography and ensure effective communication between care settings to ensure patients access to care. The EchoMD software suite assists cardiologists in automated review of images captured during echocardiograms.

Bay Labs received U.S. Food and Drug Administration (FDA) clearance for its first release of EchoMD in June 2018, which included AutoEF. AutoEF automates the calculation of left ventricular ejection fraction (EF), the single most widely used measurement of cardiac function. AutoEF relies on an Image Quality Score algorithm that quantifies the image quality of echo clips and enables display of the quality level alongside relevant images.

Edwards said the value of Bay Labs’ technology is in helping patients suffering from severe aortic stenosis, who frequently do not receive a proper diagnosis for a variety of reasons. According to a 2014 publication from the American Heart Association, aortic valve stenosis is one of the most common valvular diseases and is the third most common cardiovascular disease in developed countries. Earlier detection of heart disease, using tools like echocardiography, may lead to more appropriate treatment for these patients.

For more information: www.baylabs.io, www.edwards.com


Related Content

News | Artificial Intelligence

April 16, 2025 — An artificial intelligence (AI) program trained to review images from a common medical test can detect ...

Home April 16, 2025
Home
News | Artificial Intelligence

April 4, 2025 — Viz.ai has been named an Award Winner in the 2025 Edison Awards, for the third year in a row. Viz HCM ...

Home April 07, 2025
Home
News | Artificial Intelligence

March 3, 2025 — Microsoft Corp. has unveiled Microsoft Dragon Copilot, an AI assistant for clinical workflow that brings ...

Home March 03, 2025
Home
News | Artificial Intelligence

Feb. 25, 2025 — Heartflow, Inc., a provider of AI technology for coronary artery disease (CAD) management, recently ...

Home February 26, 2025
Home
News | Artificial Intelligence

Feb. 6, 2025 — Eko Health, a leader in applying artificial intelligence (AI) for the early detection of heart and lung ...

Home February 10, 2025
Home
News | Artificial Intelligence

Feb. 4, 2025 — Riverain Technologies recently announced it expanded across eight countries in 2024 and added nearly 50 ...

Home February 04, 2025
Home
News | Artificial Intelligence

Jan. 22, 2025 — Public Responsibility in Medicine and Research (PRIM&R) recently called for establishing clear ethical ...

Home January 23, 2025
Home
News | Artificial Intelligence

Jan. 22, 2025 -- HeartFlow, Inc., a provider of non-invasive artificial intelligence (AI) heart care solutions, and ...

Home January 23, 2025
Home
News | Artificial Intelligence

Dec. 4, 2024 – Cleerly has successfully closed its latest Series C extension funding round, raising a total of $106 ...

Home December 05, 2024
Home
News | Artificial Intelligence

Oct. 30, 2024 — HeartLung Technologies, a developer of AI tools for early detection of heart disease, lung cancer and ...

Home October 30, 2024
Home
Subscribe Now